EDB-TCR-T

EDB-TCR-T is a preclinical-stage T-cell receptor engineered T-cell (TCR-T) therapy developed by Protheragen for the treatment of solid tumors. The therapy involves engineering a patient's T cells to express a specific T-cell receptor that recognizes the Extra Domain B (EDB) of fibronectin. EDB is a splice variant of fibronectin that is highly expressed in the extracellular matrix of various solid tumors and their associated neovasculature, while being virtually absent in normal adult tissues. By targeting EDB, EDB-TCR-T aims to selectively eliminate tumor cells and disrupt the tumor microenvironment.

Other names

EDB-targeting TCR-T cell therapy